LONDON, Nov 27 (Reuters) - Britain on Friday asked its
medicine regulator to assess Oxford University and AstraZeneca's
COVID-19 vaccine candidate for temporary supply, a step
towards beginning a roll-out before the end of the year.
AstraZeneca expects 4 million doses to be available in
Britain by the end of next month, and health minister Hancock is
targeting the roll-out to begin before Christmas.
"We have formally asked the regulator to assess the
Oxford/AstraZeneca vaccine, to understand the data and determine
whether it meets rigorous safety standards," Hancock said in a
statement.
"This letter is an important step towards deploying a
vaccine as quickly as safely possible."
Britain's Medicines and Healthcare products Regulatory
Agency (MHRA) is already assessing the vaccine in a "rolling
review" as data comes in on safety and efficacy.
Hancock has also asked the MHRA to approve the
Pfizer/BioNTech candidate after it was shown to be 95%
effective.
Oxford and AstraZeneca published interim efficacy
results on Monday, which showed that the vaccine could be 90%
effective when given as a half dose followed by a full dose.
Questions have been raised about the Oxford/AstraZeneca data
and the robustness of that result, though the MHRA approved the
use of the half-dose/full-dose regime a subgroup received in the
trial.
Britain's top science adviser said on Thursday that the
interim results showed the Oxford/AstraZeneca vaccine worked.
"The headline result is the vaccine works and that's very
exciting," Patrick Vallance said during a news conference with
Prime Minister Boris Johnson. Chief Medical Officer Chris Whitty
said it was up to the regulator to make an assessment.
(Reporting by Alistair Smout
Editing by William Schomberg)